Literature DB >> 17469936

Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults.

Angela P Makris1, Craig R Rush, Robert C Frederich, Alisia C Taylor, Thomas H Kelly.   

Abstract

Modafinil is indicated for the management of excessive daytime sleepiness; however, recent studies have examined a broad range of potential uses. Given that clinical uses of modafinil may be expanding, this study compared modafinil and d-amphetamine effects on subjective and performance measures. Across 11 sessions, 11 healthy adults were tested after oral doses of placebo (5 sessions), modafinil (1.75 mg/kg, 3.50 mg/kg, or 7.00 mg/kg), and d-amphetamine (0.035 mg/kg, 0.070 mg/kg, 0.140 mg/kg) under double-blind, randomized conditions. Assessments of cognitive performance and subjective effects were completed before drug administration, 30 min after drug administration, and at hourly intervals after drug administration for 5 hr. Modafinil increased ratings on the Amphetamine and Morphine Benzedrine Group scales of the Addiction Research Center Inventory (ARCI) and increased ratings on the Vigor and Total Positive scales of the Profile of Mood States. d-Amphetamine increased visual analog ratings of feeling stimulated and liking the drug and increased ratings on the Morphine Benzedrine Group scale of the ARCI. Both medications significantly reduced visual analog scale ratings of feeling sleepy, and modafinil decreased ratings on the ARCI Pentobarbital-Chlorpromazine-Alcohol Group scale. Both medications sustained performance that deteriorated across time on the Sternberg Number Recognition Test. Modafinil also enhanced performance rate on the Digit-Symbol Substitution Task above baseline levels and increased response rate on the Repeated Acquisition of Response Sequences Task. These results suggest that modafinil engenders alerting effects and increases performance in healthy non-sleep-deprived individuals comparable with that of d-amphetamine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17469936     DOI: 10.1037/1064-1297.15.2.123

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  25 in total

Review 1.  Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function.

Authors:  Christopher J Edgar; Edward F Pace-Schott; Keith A Wesnes
Journal:  Hum Psychopharmacol       Date:  2009-07       Impact factor: 1.672

Review 2.  Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure.

Authors:  L-S Camilla d'Angelo; George Savulich; Barbara J Sahakian
Journal:  Br J Pharmacol       Date:  2017-05-12       Impact factor: 8.739

3.  Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.

Authors:  Xavier Castells; Lídia Blanco-Silvente; Ruth Cunill
Journal:  Cochrane Database Syst Rev       Date:  2018-08-09

4.  Acute effects of lisdexamfetamine and D-amphetamine on social cognition and cognitive performance in a placebo-controlled study in healthy subjects.

Authors:  Patrick C Dolder; Petra Strajhar; Patrick Vizeli; Alex Odermatt; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2018-02-09       Impact factor: 4.530

5.  The effects of progesterone pretreatment on the response to oral d-amphetamine in Women.

Authors:  Stephanie C Reed; Frances R Levin; Suzette M Evans
Journal:  Horm Behav       Date:  2010-04-24       Impact factor: 3.587

6.  A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction.

Authors:  G P Galloway; R Buscemi; J R Coyle; K Flower; J D Siegrist; L A Fiske; M J Baggott; L Li; D Polcin; C Y A Chen; J Mendelson
Journal:  Clin Pharmacol Ther       Date:  2010-12-22       Impact factor: 6.875

7.  Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.

Authors:  Katherine R Marks; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

Review 8.  Neurocognitive enhancement or impairment? A systematic meta-analysis of prescription stimulant effects on processing speed, decision-making, planning, and cognitive perseveration.

Authors:  Marisa E Marraccini; Lisa L Weyandt; Joseph S Rossi; Bergljot Gyda Gudmundsdottir
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

9.  Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study.

Authors:  Sarah A Morrow; Audrey Smerbeck; Kara Patrick; Diane Cookfair; Bianca Weinstock-Guttman; Ralph H B Benedict
Journal:  J Neurol       Date:  2012-09-23       Impact factor: 4.849

10.  Modafinil and sleep architecture in an inpatient-outpatient treatment study of cocaine dependence.

Authors:  Peter T Morgan; Gustavo A Angarita; Sofija Canavan; Brian Pittman; Lindsay Oberleitner; Robert T Malison; Vahid Mohsenin; Sarah Hodges; Caroline Easton; Sherry McKee; Andrew Bessette; Erica Forselius
Journal:  Drug Alcohol Depend       Date:  2016-01-08       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.